Retail Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Retail Press Releases.

Press releases published on October 5, 2026

Curia ลงทุน 28 ล้านดอลลาร์สหรัฐฯ ในการผลิตสารออกฤทธิ์ทางเภสัชกรรม (Active Pharmaceutical Ingredient: API) ปลอดเชื้อ
Curia 投资 2,800 万美元扩大无菌原料药产能
Curia 投資 2,800 萬美元於無菌有效藥劑成分製造
Kaplan Fox Reminds Investors of DICK’s Sporting Goods, Inc. (NYSE: DKS) to a Securities Class Action Deadline – Contact the Firm Before November 3, 2026
Fat Brain Toys Launches Air Toobz Evo, The Newest Evolution in Air-Powered Play
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
Kaplan Fox Alerts Investors of a Securities Class Action Against Beta Bionics, Inc. (NASDAQ: BBNX) – Deadline is November 3, 2026
Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway
Aprea Therapeutics to Present at October Conferences
Kaplan Fox Announces the Lead Plaintiff Deadline of October 20, 2026 in the Securities Class Action Against GoDaddy Inc. (NYSE: GDDY)
Navitas and Microchip Collaborate to Deliver 800V Reference Design for Next-Generation AI Data Centers
IES Holdings Completes Acquisition of DBM Global
AVEX Class Action Reminder: Robbins LLP Encourages AEVEX Corp. Investors to Contact the Firm for Information About Their Rights
Canadians most likely to give up on homeownership as housing costs force difficult trade-offs, global survey finds
Selon un sondage mondial, les Canadiens et Canadiennes sont les plus susceptibles de renoncer à l’accession à la propriété, les coûts du logement les obligeant à faire des choix difficiles
Medela Recognised by Australian Mums with Three MumPower Approved™ Seals
BEYYON Rechargeable Hand Warmers with LED Displays: Two Market-Tested Cold-Weather Essentials, Each in a 2-Pack
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Cerevance Appoints Karl Kieburtz, M.D., M.P.H., as Chief Medical Officer

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Retail Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.